|

Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma

RECRUITINGSponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna
Actively Recruiting
SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna
Started2024-09-15
Est. completion2026-10-15
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06777628

Summary

The study is aimed to test the performance of a simple, easy, reproducible cytofluorimetric assay to complement imaging studies for: * predicting response to immune-therapeutic regimens in HCC in the early phase of treatment, * to rule out pseudo-progression, * to early predict the escape from effectiveness of treatment.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* age ≥ 18 years
* diagnosis of HCC
* execution of laboratory tests and subsequent treatments and follow-up at our center.
* obtained written informed consent to the study participation

Exclusion Criteria:

* immune-related concomitant diseases
* HIV infection

Conditions4

CancerLiver CancerLiver Cancer, AdultLiver Disease

Browse More Trials

Cancer trialsLiver Disease trialsLiver Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.